Results 61 to 70 of about 6,226 (154)

In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study

Arquivos Brasileiros de Cardiologia
Background: Despite successful opening of culprit coronary artery, myocardial reperfusion does not always follows primary percutaneous coronary intervention (PPCI).
Igor Matos Lago, Gustavo Caires Novaes, André Vannucchi Badran, Rafael Brolio Pavão, Ricardo Barbosa, Geraldo Luiz de Figueiredo, Moysés de Oliveira Lima Filho, Jorge Luiz Haddad, André Schmidt, José Antônio Marin Neto   +9 more
doaj   +1 more source

The role of intravenous tirofiban in patients undergoing endovascular treatment for acute intracranial atherosclerotic occlusion

Journal of Stroke and Cerebrovascular Diseases
BACKGROUND AND PURPOSE: Previous reports regarding the impact of tirofiban on patients undergoing endovascular treatment for acute ischemic stroke have shown inconsistencies.
Zhiping Bu, MD, Dapeng Sun, MD, Xiaoli Zhang, PhD, Ning Ma, MD, Feng Gao, MD, Dapeng Mo, MD, Qingwei Meng, MD, Zhongrong Miao, MD   +7 more
doaj   +1 more source

The safety and efficacy of intra-arterial low-dose tirofiban administration during endovascular therapy in patients with large ischemic core volume

Scientific Reports
This study aimed to evaluate the safety and efficacy of intra-arterial (IA) administration of low- dose tirofiban during endovascular therapy in patients with large ischemic core volumes on initial brain CT. Patients were divided into two groups based on
Kwang-Chun Cho, Nak-Hoon Son, So Hyeon Gwon, Jin Wook Choi, Woo Sang Jung   +4 more
doaj   +1 more source

Cost-effectiveness of tirofiban for acute ischemic stroke without large or medium-sized vessel occlusion: A Markov modelling analysis from the Chinese and United States perspectives.

PLoS ONE
BackgroundThe RESCUE BT2 trial recently showcased the efficacy of tirofiban in treating acute ischemic stroke (AIS) without large or medium-sized vessel occlusion.
Li Wang, Yuhong Zeng, Limei Zhou, Ping Xu, Xianbin Guo, Yu Xie, Junxiu Cai, Min Pan, Jie Tang, Qingtao Gong, Rong Su, Yan Liu, Yake Lou   +12 more
doaj   +1 more source

Tirofiban-induced acute profound thrombocytopenia in endovascular therapy for acute ischemic stroke: a rare case report

BMC Neurology
Background Studies have shown that tirofiban (a glycoprotein IIb/IIIa receptor antagonist) is effective in the endovascular treatment of cerebrovascular diseases. However, it has also been reported that tirofiban can cause thrombocytopenia.
Jiuling Liu, Melysze Deanne Oorloff, Adithya Nadella, Yun Yan, Ning Zhou   +4 more
doaj   +1 more source

Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome

São Paulo Medical Journal
CONTEXT AND OBJECTIVES: Glycoprotein inhibitors (abciximab, eptifibatide and tirofiban) are used in patients with unstable angina and non-ST-segment elevation myocardial infarction before percutaneous coronary intervention.
Antonio de Padua Mansur, Alessandra Roggerio, Júlio Yoshio Takada, Pérola Michelle Vasconcelos Caribé, Solange Desirée Avakian, Célia Maria Cassaro Strunz   +5 more
doaj   +1 more source

Desenlaces clínicos en una cohorte de pacientes con síndrome coronario agudo y administración intracoronaria de tirofiban

Revista Colombiana de Cardiología, 2015
Introducción: Los inhibidores de glicoproteína IIb/IIIa reducen los eventos cardiovasculares mayores adversos (MACE) en pacientes con síndrome coronario agudo.
Julián Ochoa, Jorge G. Velásquez, Jorge A. Cedano, Camila Ospina, Lina Merchancano, Diana C. Carrillo   +5 more
doaj   +1 more source

Effect of Intravenous Tirofiban Versus Placebo on First‐Pass Successful Reperfusion in Endovascular Stroke Thrombectomy: Insights From the RESCUE BT Randomized Clinical Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background First‐pass successful reperfusion (FPSR), defined as a successful/complete reperfusion achieved after a single thrombectomy pass, is predictive of favorable outcome in patients with acute ischemic stroke with large‐vessel occlusion.
Junjie Yuan, Hanming Ge, Zhaojun Tao, Huijie An, Qin Han, Jeffrey L. Saver, Thanh N. Nguyen, Simin Zhou, An Mao, Yuelu Wu, Raul Gomes Nogueira, Yaxuan Sun, Shunfu Jiang, Liping Wei, Xinmin Fu, Yongjie Bai, Shunyu Yang, Wei Hu, Guling Zhang, Chengde Pan, Shuai Zhang, Lin Qiao, Qiong Chen, Hongfei Sang, Zhongming Qiu, Fengfu Wu, Mingze Chang, Zhongfan Ruan   +27 more
doaj   +1 more source

Tirofiban Combination Therapy for Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis

Brain and Behavior
Introduction Acute ischemic stroke (AIS) is a leading cause of morbidity and mortality globally. Standard antiplatelet therapies, while partially effective, do not fully inhibit all pathways of platelet aggregation, leaving patients at risk of recurrent ...
Abdullah Bin Kamran, Ahmed Bazil Bin Khalil, Ayesha Muhammad, Hira Arshad, Fatima Nazir, Muhammad Mateen Ali, M. Mairaj Umar, Muhammad Farhan, Sudhair Alam, Javed Iqbal   +9 more
doaj   +1 more source

Efficacy and safety of early tirofiban administration after intravenous thrombolysis in patients with acute ischaemic stroke: the multicentre, randomised, double-blind, placebo-controlled RESCUE BT3 trial protocol. [PDF]

Eur Stroke J
Li F, Fan S, Guo C, Li G, Yang J, Song J, Yang D, Li L, Nguyen TN, Zi W, Yang Q.   +10 more
europepmc   +1 more source